Solomon Moshkevich Net Worth

The estimated Net Worth of Solomon Moshkevich is at least $22.2 Milión dollars as of 29 July 2024. Solomon Moshkevich owns over 1,196 units of Natera Inc stock worth over $13,923,569 and over the last few years Solomon sold NTRA stock worth over $8,272,562.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Solomon Moshkevich NTRA stock SEC Form 4 insiders trading

Solomon has made over 9 trades of the Natera Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Solomon sold 1,196 units of NTRA stock worth $122,913 on 29 July 2024.

The largest trade Solomon's ever made was selling 80,000 units of Natera Inc stock on 16 April 2024 worth over $7,265,600. On average, Solomon trades about 9,150 units every 18 days since 2024. As of 29 July 2024 Solomon still owns at least 112,441 units of Natera Inc stock.

You can see the complete history of Solomon Moshkevich stock trades at the bottom of the page.

What's Solomon Moshkevich's mailing address?

Solomon's mailing address filed with the SEC is C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN, TX, 78753.

Insiders trading at Natera Inc

Over the last 14 years, insiders at Natera Inc have traded over $290,138,276 worth of Natera Inc stock and bought 2,046,493 units worth $38,018,986 . The most active insiders traders include Matthew Rabinowitz, James Healy a Roelof Botha. On average, Natera Inc executives and independent directors trade stock every 9 days with the average trade being worth of $3,415,231. The most recent stock trade was executed by Steven Leonard Chapman on 15 August 2024, trading 5,583 units of NTRA stock currently worth $663,875.

What does Natera Inc do?

natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the

Complete history of Solomon Moshkevich stock trades at Natera Inc

Natera Inc executives and stock owners

Natera Inc executives and other stock owners filed with the SEC include:

• Steven Chapman,
  President, Chief Executive Officer, Director
• Robert Schueren,
  Chief Operating Officer
• Michael Brophy,
  Chief Financial Officer
• Matthew Rabinowitz,
  Executive Chairman of the Board, Co-Founder
• Steve Leonard Chapman,
  CEO, Pres & Director
• Jonathan Sheena,
  Co-Founder, Chief Technology Officer, Director
• Robert A. Schueren,
  Chief Operating Officer
• Steve Chapman,
  CEO, Pres & Director
• Michael Brophy,
  Chief Financial Officer
• Rowan Chapman,
  Independent Director
• Dr. Matthew Rabinowitz Ph.D.,
  Co-Founder & Exec. Chairman
• Gail Marcus,
  Independent Director
• Roelof Botha,
  Lead Independent Director
• Todd Cozzens,
  Independent Director
• James Healy,
  Independent Director
• Herman Rosenman,
  Independent Director
• Roy Baynes,
  Independent Director
• Jonathan Sheena,
  Co-Founder & Director
• Monica Bertagnolli,
  Independent Director
• Rishi Kacker,
  Chief Technology Officer
• Paul Greenland,
  VP of Corp. Marketing
• Dr. Ramesh Hariharan,
  VP of Marketing & Medical Education
• Phil Grinnell,
  VP of Sales
• Daniel Rabinowitz L.L.M., LL.M.,
  Sec. & Gen. Counsel
• Eric A. Evans,
  Chief Scientific Officer
• John Steuart,
  Director
• John Fesko,
  PRESIDENT, CHIEF BUS. OFFICER
• Creek Ventures L P Claremon...,
  
• Solomon Moshkevich,
  PRESIDENT, CLINICALDIAGNOSTICS
• Creek Ventures L P Claremon...,
  
• Creek Ventures L P Claremon...,
  
• Venture Partners Viii Lp Li...,
  
• Xii Management Llcsequoia C...,
  
• Daniel Rabinowitz,
  SEC. AND CHIEF LEGAL OFFICER
• Herm Rosenman,
  
• Brinkley Ruth Williams,